(CercleFinance.com) – Bristol Myers Squibb reports that the US FDA has approved Reblozyl as a first-line treatment for anemia in adults with low-risk myelodysplastic syndromes (MDS) who may require transfusions.
‘Reblozyl is the first and only treatment to demonstrate superiority over an erythropoiesis-stimulating agent (ESA) in MDS-related anemia based on interim results from the pivotal phase III COMMANDS trial’, points out the health group.
The results of this study were presented in June at the annual meeting of the American Society of Clinical Oncology (ASCO). Reblozyl has been developed and commercialized in a global collaboration with Merck since November 2021.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
